Clinical Trial Update: Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG [Phase 1]

View source ↗

Summary

Phase I trial evaluating safety, distribution, and radiation dosimetry of ultratrace iobenguane I-123 (MIBG); the study in neuroendocrine tumors and heart failu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Neuroendocrine Tumor

Drugs mentioned

• iobenguane I-123 (iobenguane I-123)

Snippet

Sponsor: Bennett Chin | Conditions: Neuroendocrine Tumors, Heart Failure | Phase 1 | Status: COMPLETED